Trial
NCT04539483
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Heidelberg ImmunoTherapeutics GmbH
Collaborators
—
Condition
Herpes Labialis
Intervention
HDIT101 (blinded therapy)
Why stopped
stopped for futility in interim analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-25